Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 2Sarcoma 2Genitourinary 2Gastrointestinal 2Dermatologic 2Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 3Recurrence 2Neoplasms 1Myelodysplastic Syndromes 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × milademetan × Other hematologic neoplasm × Clear all
NCT03671564 2023-11-07

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Daiichi Sankyo

Phase 1 Completed
14 enrolled 14 charts
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT03552029 2022-05-20

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Daiichi Sankyo

Phase 1 Terminated
10 enrolled 10 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02319369 2021-10-11

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Daiichi Sankyo

Phase 1 Terminated
74 enrolled 30 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡